ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 29 for:    axium

A Multi-Centre RCT of the Axium® Neurostimulator for the Treatment of Chronic Inguinal Pain Following Surgery (SMASHING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02349659
Recruitment Status : Terminated (Sponsor withdrawn due to low inclusion rate)
First Posted : January 29, 2015
Last Update Posted : February 1, 2017
Sponsor:
Information provided by (Responsible Party):
Frederique Mol, Maxima Medical Center

Brief Summary:
24-SMI-2014 is a Randomised Controlled Trial with an optional one way cross-over comparing Conservative Medical Management (CMM) to treatment with the Axium neurostimulator + CMM. Subject population is chronic inguinal pain refractory to previous surgical intervention (neurectomy).

Condition or disease Intervention/treatment Phase
Chronic Inguinal Pain Refractory to Previous Surgical Intervention (Neurectomy) Device: Implantation with the commercially available Axium neurostimulator Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Controlled Trial to Evaluate the Efficacy of the Spinal Modulation Axium® NeuroStimulator THerapy as a Treatment for Persistent INGuinal Pain Following Surgical Intervention: SMASHING
Study Start Date : December 2014
Estimated Primary Completion Date : July 2017
Estimated Study Completion Date : October 2017

Arm Intervention/treatment
No Intervention: Conservative Medical Management
Continued medical management restricted to exclude interventional pain treatments
Active Comparator: Axium Group
As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
Device: Implantation with the commercially available Axium neurostimulator



Primary Outcome Measures :
  1. Percentage of subjects experiencing ≥50% reduction in average daily pain intensity in the Axium Group as compared to the CMM only group using an eleven point (0-10) numerical pain rating scale (NPRS) [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is at least 18 years old
  2. Subject is able and willing to comply with the follow-up schedule and protocol
  3. Chronic inguinal pain following Pfannenstiel Incision or Open Inguinal Hernia Repair for at least 6 months
  4. Previously undergone neurectomy procedure as a treatment for chronic inguinal pain
  5. Minimum daily average baseline pain rating of 5 out of 10 in the inguinal area on an 11-point NPRS
  6. Subject is able to provide written informed consent
  7. Meets of the inclusion criteria for the implantation of a neurostimulation system as set out by the Dutch Neuromodulation Society
  8. Subject has been screened by a multi-disciplinary panel including the designated psychologist of the Máxima Medical Center and deemed suitable for implantation

Exclusion Criteria:

  1. Female subject of childbearing potential is pregnant/nursing or plans to become pregnant during the course of the Trial
  2. Escalating or changing pain condition within the past month as evidenced by investigator examination
  3. Subject has had injection therapy or radiofrequency treatment of a target neural structure within the past 3 months
  4. Subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump
  5. Subject is unable to operate the device
  6. Subjects currently has an active infection
  7. Subject has participated in another clinical investigation within 30 days
  8. Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation
  9. Subject has a current or on going condition, which will probably require MRI investigation sometime in the following 2 years
  10. Subject has had a spinal surgical procedure at or between vertebral levels T10-L2
  11. Subject has been diagnosed with cancer in the past 2 years, except for skin malignancies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02349659


Locations
Netherlands
Máxima Medisch Centrum
Eindhoven, Netherlands
Sponsors and Collaborators
Maxima Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Frederique Mol, drs., Maxima Medical Center
ClinicalTrials.gov Identifier: NCT02349659     History of Changes
Other Study ID Numbers: 24-SMI-2014
First Posted: January 29, 2015    Key Record Dates
Last Update Posted: February 1, 2017
Last Verified: January 2017